Fezolinetant
Fezolinetant has been studied in 54 papers since 2022: 9 trials and 1 observational study in people, 1 in animals, 42 reviews; 31 in the past year. It is an approved medicine. The newest paper, Nov 18, 2026: “Non-hormonal management of menopause symptoms—the statement of the European Society of Gynecology”.
8 new papers in 30 daysSee all 60 papers on fezolinetant
At a glance
Fezolinetant reduces menopausal vasomotor symptoms in human trials, with independent labs reproducing the reduction; a review finds no clear difference versus hormone therapies. Trials report improved sleep, while adverse-event results differ. Aging-related trials are registered; across uses, most trials have developer sponsors and some ended over a year ago without posted results, while human papers declare developer ties.
53 findings in 34 papers from 2023 to 2026, 14 of them since April 2026
Independent labs found the same change in people. 14 independent labs in 10 countries; 25 trials, 16 about aging, 9 with no results posted.
“reductions in VMS frequency for fezolinetant 45 mg versus placebo were - 1.46 (-2.01, -0.92) and - 2.51 (-3.20, -1.82).”
3 of its findings point the other way.
- 14 independent labs in 10 countries
- 3 findings against
- 25 trials, 16 about aging, 9 with no results posted
- Funders: Astellas Pharma and others
- 16 of 31 findings with company ties
- 21 of 25 trials sponsored by its developers
- Human trial9
- Humans1
- Model organisms1
- In silico1
Studies in people
5 studies gave fezolinetant to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Improves sleep disturbanceLS mean difference -1.31, 95% CI -2.59, -0.02 | Randomized trial12 weeks | 1,022 peoplewomenmean age 54.3 ± 5.0 yearsPostmenopausal women seeking treatment or relief for vasomotor symptoms due to menopause | Climacteric : the journal of the International Menopause Society, Sep 14, 2026 |
down: Decreases hot flashes down: Decreases depression | Randomized trial6 months | Women40-65 years oldMidlife adults; Older adults; Postmenopausal women; associated with menopause | Women's health (London, England), Apr 3, 2026 |
down: Decreases work productivity loss22.6 vs 6.3 percentage points down: Decreases missed work hours2.8 to 4.2 work hours per week per woman | Randomized trial1 year | womenmean age of 53.8 yearsEmployed women from the SKYLIGHT 1 and 2 trials with moderate to severe VMS associated with menopause | Menopause (New York, N.Y.), Mar 31, 2026 |
down: Decreases vasomotor symptom frequencyWeek 12 least squares mean difference −2.51 (95% CI −3.20 to −1.82) | Randomized trial12 weeks | 1,022 peopleWomen≥40-≤65 yearsMidlife adults; Older adults; moderate to severe vasomotor symptoms associated with menopause | Maturitas, Oct 6, 2025 |
down: Decreases daily frequency of moderate-severe vasomotor symptomsLeast squares mean difference -1.93, 95% CI -2.64 to -1.22 down: Decreases sleep disturbancePROMIS SD-SF 8b total score difference -2.5, 95% CI -3.9 to -1.1; P<0.001 no change: Has no effect on treatment-emergent adverse eventsTEAEs: 65.0% versus 61.1%; serious TEAEs: 4.4% versus 3.5% | Randomized trial24 weeks | 452 people40-65 yearsMidlife adults; Menopause; unsuitable for hormone therapy | BMJ (Clinical research ed.), Nov 18, 2024 |
What did studies of fezolinetant find?
21Studies of fezolinetant measured 21 outcomes; the most studied are vasomotor symptoms (9 studies), vasomotor symptoms (7) and vasomotor symptom frequency (3).
Vasomotor symptoms
downin humans6upin humans3
9 studies
Vasomotor symptoms
downin humans6upin humans3
Fezolinetant decreases vasomotor symptoms in humans (moderate to severe vasomotor symptoms due to menopause).
“Fezolinetant reduced moderate to severe VMS due to menopause”
Human trialmoderate to severe vasomotor symptoms due to menopause1 year
Effect of fezolinetant on sleep, health-related quality of life and work productivity
Climacteric : the journal of the International Menopause Society
Fezolinetant decreases vasomotor symptoms in humans (menopause).
“newly Food and Drug Administration (FDA)-approved NK3 receptor antagonists (e.g., fezolinetant), and structured plant-based dietary restructuring—offer substantial symptom reduction.”
Reviewmenopause
Clinical and Experimental Obstetrics & Gynecology
Fezolinetant decreases vasomotor symptoms in humans (menopausal VMS in the general population).
“Fezolinetant, a selective NK3 receptor antagonist approved for menopausal VMS in the general population, has shown robust efficacy across multiple phase III trials”
Reviewmenopausal VMS in the general population
Breast (Edinburgh, Scotland)
Fezolinetant decreases vasomotor symptoms in humans.
“Fezolinetant, a selective NK 3 receptor antagonist, and elinzanetant, a dual NK1/NK3 receptor antagonist, provide rapid and clinically meaningful reductions in VMS”
Review
Neurokinin 3 Receptor Antagonists for Menopause Symptom Management
Obstetrics and gynecology clinics of North America
Fezolinetant decreases vasomotor symptoms in patients with absolute contraindications to MHT.
“the approval of neurokinin-3 (NK3) receptor antagonists (fezolinetant and elinzanetant) represents a paradigm shift in mitigating VMS via direct hypothalamic modulation”
Reviewin patients with absolute contraindications to MHT
International Journal of Drug Delivery Technology
Fezolinetant decreases vasomotor symptoms in humans (menopausal vasomotor symptoms).
“demonstrate reduced frequency of vasomotor symptoms with their use”
Reviewmenopausal vasomotor symptomsfemales
Where do neurokinin receptor antagonists fit into management of menopausal vasomotor symptoms?
JAAPA : official journal of the American Academy of Physician Assistants
Fezolinetant improves vasomotor symptoms in patients without a history of breast cancer.
“Fezolinetant is a novel neurokinin 3 receptor antagonist that has demonstrated clinical benefit in patients without a history of breast cancer.”
Reviewin patients without a history of breast cancer
Expert review of clinical pharmacology
Fezolinetant improves vasomotor symptoms in humans (moderate-to-severe VMS).
“Recent three randomized clinical trials (RCTs), including SKYLIGHT 1,2, and 4 confirmed the safety and efficacy for treating moderate-to-severe VMS women.”
Reviewmoderate-to-severe VMSfemales
Menopause part I: Vasomotor symptoms (I)
Taiwanese journal of obstetrics & gynecology
Fezolinetant improves vasomotor symptoms in humans (menopause).
“In 2023, the FDA approved fezolinetant, the first selective NK3R antagonist, for the treatment of moderate to severe VMS associated with menopause.”
Reviewmenopause
A New Hope for Woman with Vasomotor Symptoms: Neurokinin B Antagonists
Journal of clinical medicine
Vasomotor symptoms
downin humans6downin reviews1−60% vms
7 studies
Vasomotor symptoms
downin humans6downin reviews1−60% vms
Fezolinetant decreases vasomotor symptoms in humans (postmenopausal women; compared with placebo) (60% to 70% reduction in VMS intensity).
“Fezolinetant was shown to be effective and safe in reducing the frequency and severity of vasomotor symptoms (VMS) compared with placebo in postmenopausal women.”
Reviewpostmenopausal women; compared with placebofemales
Universitas Médica
Fezolinetant decreases vasomotor symptoms (60% decrease in VMS).
“Non-hormonal Neurokini3 antagonists like fezolinetant, decreased VMS by 60% and benefited high-risk patients.”
Review
Innovative Drug Delivery Systems for Management of Menopausal Symptoms: A Systematic Review
International journal of women's health
Fezolinetant decreases vasomotor symptoms in humans (menopause) (50%-65% reduction).
“NK3R antagonists (fezolinetant, 50%-65% VMS reduction)”
Reviewmenopausefemales
Frontiers in reproductive health
Fezolinetant decreases vasomotor symptoms in humans (postmenopausal women).
“Emerging treatments like fezolinetant demonstrate promise in reducing VMS by addressing the underlying pathophysiology”
Reviewpostmenopausal womenfemales
Treatment of Menopausal Symptoms When Hormone Therapy Is Contraindicated
Seminars in reproductive medicine
Fezolinetant decreases vasomotor symptoms in humans (menopause).
“Fezolinetant has shown efficacy in reducing the frequency and severity of VMS”
Reviewmenopause
Expert opinion on drug metabolism & toxicology
Fezolinetant decreases vasomotor symptoms in menopausal women.
“NK3R antagonists provide a safe and effective treatment option for managing menopausal women with VMS.”
Reviewin menopausal women
European journal of obstetrics, gynecology, and reproductive biology
Fezolinetant decreases vasomotor symptoms in humans (associated with menopause; compared with placebo).
“Clinical trials have demonstrated fezolinetant is superior to placebo in decreasing the frequency and severity of vasomotor symptoms.”
Reviewassociated with menopause; compared with placebo
Fezolinetant: A New Nonhormonal Treatment for Vasomotor Symptoms
The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians
Vasomotor symptom frequency
downin humans3no changein humans1
3 studies
Vasomotor symptom frequency
downin humans3no changein humans1
Fezolinetant decreases vasomotor symptom frequency in humans (moderate to severe vasomotor symptoms associated with menopause; versus placebo) (Week 12 least squares mean difference −2.51 (95% CI −3.20 to −1.82)).
“reductions in VMS frequency for fezolinetant 45 mg versus placebo were - 1.46 (-2.01, -0.92) and - 2.51 (-3.20, -1.82).”
Human trialmoderate to severe vasomotor symptoms associated with menopause; versus placebo45 mg12 weeksassigned female at births
Maturitas
Fezolinetant decreases vasomotor symptom frequency in humans (menopause; compared with other nonhormone therapies).
“Fezolinetant has been shown to result in a significant reduction in vasomotor symptom frequency when compared to other nonhormone therapies”
Reviewmenopause; compared with other nonhormone therapies
Cooling the flames: Navigating menopausal vasomotor symptoms with nonhormone medications
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Fezolinetant showed no clear effect on vasomotor symptom frequency in humans (Postmenopausal women; compared with 27 hormone therapy regimens).
“Changes in VMS frequency did not differ significantly between fezolinetant 45 mg and any of the 27 HT regimens studied.”
ReviewPostmenopausal women; compared with 27 hormone therapy regimens45 mg12 weeksfemales
Menopause (New York, N.Y.)
Fezolinetant decreases vasomotor symptom frequency in humans (Postmenopausal women; compared with other nonhormone therapies).
“Fezolinetant 45 mg once daily was statistically significantly more effective than other non-HTs in reducing the frequency of moderate to severe VMS.”
ReviewPostmenopausal women; compared with other nonhormone therapies45 mg once daily12 weeksfemales
Menopause (New York, N.Y.)
Sleep disturbance
upin humans1downin humans1
2 studies
Sleep disturbance
upin humans1downin humans1
Fezolinetant improves sleep disturbance in humans (LS mean difference -1.31, 95% CI -2.59, -0.02).
“Fezolinetant 30 mg and 45 mg improved sleep disturbance over the past 7 days (PROMIS SD-SF-8b total score) from baseline to 12 weeks versus placebo.”
Human trial45 mg12 weeksn = 648
Effect of fezolinetant on sleep, health-related quality of life and work productivity
Climacteric : the journal of the International Menopause Society
Fezolinetant improves sleep disturbance in humans (moderate to severe vasomotor symptoms due to menopause).
“Fezolinetant 30 mg and 45 mg improved sleep disturbance and impairment versus placebo at 12 weeks”
Human trialmoderate to severe vasomotor symptoms due to menopause12 weeks
Effect of fezolinetant on sleep, health-related quality of life and work productivity
Climacteric : the journal of the International Menopause Society
Fezolinetant decreases sleep disturbance in humans (Menopause; unsuitable for hormone therapy; compared with placebo) (PROMIS SD-SF 8b total score difference -2.5, 95% CI -3.9 to -1.1; P<0.001).
“At week 24, the fezolinetant group had a greater reduction in sleep disturbance (PROMIS SD-SF 8b total score) compared with placebo”
Human trialMenopause; unsuitable for hormone therapy; compared with placebo45 mg once daily24 weeksn = 452
BMJ (Clinical research ed.)
Vasomotor symptom frequency and severity
downin humans2
2 studies
Vasomotor symptom frequency and severity
downin humans2
Fezolinetant decreases vasomotor symptom frequency and severity in humans (menopause; compared with placebo).
“The studies demonstrated that both drugs significantly reduce the frequency and severity of vasomotor symptoms compared with placebo”
Reviewmenopause; compared with placebofemales
Research Society and Development
Fezolinetant decreases vasomotor symptom frequency and severity in humans (postmenopause).
“fezolinetant, a neurokinin-3 receptor antagonist and elinzanetant, a neurokinin-1-3 receptor antagonist, diminish the frequency and severity of vasomotor symptoms.”
Reviewpostmenopausefemales
Journal of clinical medicine
Quality of life
upin humans2
2 studies
Quality of life
upin humans2
Fezolinetant improves quality of life in humans (postmenopausal women).
“It also improves quality of life and sleep disturbances, with an adequate safety profile.”
Reviewpostmenopausal womenfemales
Universitas Médica
Fezolinetant improves quality of life in humans (menopause).
“with a positive impact on sleep- and health-related QoL and acceptable safety and tolerability profile.”
Reviewmenopause
Expert opinion on drug metabolism & toxicology
Work productivity loss
downin humans1
1 study
Work productivity loss
downin humans1
Fezolinetant decreases work productivity loss in population 1 (22.6 vs 6.3 percentage points).
“After 1 year of treatment with fezolinetant or placebo, overall work productivity loss improved by 22.6 and 6.3 percentage points, respectively, in population 1 and by 22.5 and 9.8 percentage points, respectively, in population 2.”
Human trialin population 11 year
Menopause (New York, N.Y.)
Fezolinetant decreases work productivity loss in humans (post hoc analysis of SKYLIGHT 1, SKYLIGHT 2, and DAYLIGHT trials) (-12.4% (population 1), -10.2% (population 2)).
“Overall work productivity loss improved with fezolinetant versus placebo (population 1: -12.4% [ P <0.0001]; population 2: -10.2% [ P <0.0001]).”
Human trialpost hoc analysis of SKYLIGHT 1, SKYLIGHT 2, and DAYLIGHT trials52 weeksfemales
Menopause (New York, N.Y.)
Thermotaxis behavior
upin worms1
1 study
Thermotaxis behavior
upin worms1
Fezolinetant improves thermotaxis behavior in worms (nlp-58 overexpression).
“partially improved the thermotaxis defect caused by nlp-58 overexpression.”
Model organismsnlp-58 overexpression
PLoS genetics
Menopausal vasomotor symptoms
downin humans1
1 study
Menopausal vasomotor symptoms
downin humans1
Fezolinetant decreases menopausal vasomotor symptoms in humans (MHT contraindicated or not preferred).
“non-hormonal drugs, such as paroxetine, fezolinetant and elinzanetant, offer effective alternative treatment options.”
ReviewMHT contraindicated or not preferred
Drugs & Therapy Perspectives
Hot flash frequency
downin humans1−21% reduction after accounting for placebo response
1 study
Hot flash frequency
downin humans1−21% reduction after accounting for placebo response
Fezolinetant decreases hot flash frequency in humans (menopausal hot flashes) (20.6% reduction after accounting for placebo response).
“At the recommended doses, fezolinetant (45 mg) and elinzanetant (120 mg) achieved reductions of 20.6% and 19.6%, respectively.”
Reviewmenopausal hot flashes45 mgfemales
Menopause (New York, N.Y.)
Depression
downin humans1
1 study
Depression
downin humans1
Fezolinetant decreases depression in humans (associated with menopause).
“Participants taking fezolinetant also had greater improvements in sleep, quality of life, depression, and work productivity.”
Human trialassociated with menopausepill6 monthsfemales
Women's health (London, England)
Hot flashes
downin humans1
1 study
Hot flashes
downin humans1
Fezolinetant decreases hot flashes in humans (associated with menopause).
“Compared with the placebo, fezolinetant reduced the number of hot flashes that participants had each day.”
Human trialassociated with menopausepill6 monthsfemales
Women's health (London, England)
Missed work hours
downin humans1
1 study
Missed work hours
downin humans1
Fezolinetant decreases missed work hours in population 1 (2.8 to 4.2 work hours per week per woman).
“Overall, this corresponded to an increase of 2.8 to 4.2 work hours per week per woman treated with fezolinetant versus placebo in population 1.”
Human trialin population 11 year
Menopause (New York, N.Y.)
Treatment-emergent adverse events
no changein humans1
1 study
Treatment-emergent adverse events
no changein humans1
Fezolinetant showed no clear effect on treatment-emergent adverse events in humans (Menopause; unsuitable for hormone therapy; compared with placebo) (TEAEs: 65.0% versus 61.1%; serious TEAEs: 4.4% versus 3.5%).
“Both groups showed similar incidences of treatment emergent adverse events”
Human trialMenopause; unsuitable for hormone therapy; compared with placebo45 mg once daily24 weeksn = 452
BMJ (Clinical research ed.)
Daily frequency of moderate-severe vasomotor symptoms
downin humans1
1 study
Daily frequency of moderate-severe vasomotor symptoms
downin humans1
Fezolinetant decreases daily frequency of moderate-severe vasomotor symptoms in humans (Menopause; unsuitable for hormone therapy; compared with placebo) (Least squares mean difference -1.93, 95% CI -2.64 to -1.22).
“At week 24, fezolinetant significantly reduced the frequency (least squares mean difference -1.93, 95% confidence interval (CI) -2.64 to -1.22; P<0.001)”
Human trialMenopause; unsuitable for hormone therapy; compared with placebo45 mg once daily24 weeksn = 452
BMJ (Clinical research ed.)
All 21Fewer
What is fezolinetant linked with?
10Studies link fezolinetant with 10 measures, among them non-benign neoplasms, nightmare and gamma-glutamyltransferase.
Non-benign neoplasms
upin humans1RR 6.6
1 study
Non-benign neoplasms
upin humans1RR 6.6
Fezolinetant is associated with non-benign neoplasms in humans (Licensed-dose comparison with placebo in the SKYLIGHT phase III programme) (RR 6.6 (95% CI 0.9–51.3)).
“giving a relative risk at the licensed dose of 6.6 (95% confidence interval 0.9-51.3)”
ReviewLicensed-dose comparison with placebo in the SKYLIGHT phase III programme45 mg
Drug safety
Nightmare
upin humans1
1 study
Nightmare
upin humans1
Fezolinetant is associated with nightmare in humans (primary suspect drug in FAERS) (ROR 6.61 (95% CI 3.90-11.19)).
“Nightmare (ROR 6.61, 95% CI(ROR): 3.90-11.19, PRR 6.56, 95%CI(PRR): 3.89-11.06) was detected as a potential novel safety signal”
Humansprimary suspect drug in FAERS
Real-world safety profile of fezolinetant: a disproportionality analysis based on the FAERS database
Naunyn-Schmiedeberg's archives of pharmacology
Gamma-glutamyltransferase
upin humans1
1 study
Gamma-glutamyltransferase
upin humans1
Fezolinetant is associated with gamma-glutamyltransferase in humans (primary suspect drug in FAERS) (ROR 33.58 (95% CI 24.39-46.22)).
“gamma-glutamyltransferase increased (ROR 33.58, 95% CI(ROR): 24.39-46.22, PRR 32.86, 95% CI(PRR): 24.04-44.91)”
Humansprimary suspect drug in FAERS
Real-world safety profile of fezolinetant: a disproportionality analysis based on the FAERS database
Naunyn-Schmiedeberg's archives of pharmacology
Aspartate aminotransferase
upin humans1
1 study
Aspartate aminotransferase
upin humans1
Fezolinetant is associated with aspartate aminotransferase in humans (primary suspect drug in FAERS) (ROR 41.72 (95% CI 34.97-49.76)).
“aspartate aminotransferase increased (ROR 41.72, 95%CI(ROR): 34.97-49.76, PRR 38.57, 95%CI(PRR): 32.77-45.39)”
Humansprimary suspect drug in FAERS
Real-world safety profile of fezolinetant: a disproportionality analysis based on the FAERS database
Naunyn-Schmiedeberg's archives of pharmacology
Alanine aminotransferase
upin humans1
1 study
Alanine aminotransferase
upin humans1
Fezolinetant is associated with alanine aminotransferase in humans (primary suspect drug in FAERS) (ROR 48.31 (95% CI 41.34-56.46)).
“alanine aminotransferase increased (ROR 48.31, 95%CI(ROR): 41.34-56.46, PRR 43.49, 95% CI(PRR): 37.80-50.04)”
Humansprimary suspect drug in FAERS
Real-world safety profile of fezolinetant: a disproportionality analysis based on the FAERS database
Naunyn-Schmiedeberg's archives of pharmacology
Nonbenign neoplasms
upin reviews1
1 study
Nonbenign neoplasms
upin reviews1
Fezolinetant raises the risk of nonbenign neoplasms (menopausal vasomotor symptoms).
“emerging data from meta-analysis and pooled analysis consistently showed a significant increase in the risk of nonbenign neoplasms”
Reviewmenopausal vasomotor symptoms
Journal of the Endocrine Society
Drug-induced liver injury
upin silico1
1 study
Drug-induced liver injury
upin silico1
Fezolinetant raises the risk of drug-induced liver injury in DILIsym simulations.
“DILIsym simulations indicated a dose-dependent relationship between fezolinetant exposure and hepatotoxicity primarily caused by electron transport chain inhibition.”
In silicoin DILIsym simulations
Clinical pharmacology and therapeutics
Treatment-emergent adverse events
upin humans1
1 study
Treatment-emergent adverse events
upin humans1
Fezolinetant is associated with treatment-emergent adverse events in humans (compared with placebo in women with vasomotor symptoms due to menopause) (62.9% versus 55.3% with placebo).
“TEAEs occurred in 55.3%, 62.9%, and 65.4%, respectively; exposure-adjusted results were consistent with these results.”
Reviewcompared with placebo in women with vasomotor symptoms due to menopause45 mgfemalesn = 1,100
Advances in therapy
Liver transaminases
upin humans1
1 study
Liver transaminases
upin humans1
Fezolinetant is associated with liver transaminases in humans.
“Common adverse effects associated with the use of fezolinetant include headache and gastrointestinal disturbances, as well as elevations in liver transaminase levels.”
Review
Fezolinetant: A New Nonhormonal Treatment for Vasomotor Symptoms
The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians
Headache and gastrointestinal disturbances
upin humans1
1 study
Headache and gastrointestinal disturbances
upin humans1
Fezolinetant is associated with headache and gastrointestinal disturbances in humans.
“Common adverse effects associated with the use of fezolinetant include headache and gastrointestinal disturbances, as well as elevations in liver transaminase levels.”
Review
Fezolinetant: A New Nonhormonal Treatment for Vasomotor Symptoms
The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians
Has fezolinetant been tested in people?
16 of 25 about agingYes: 9 trials and 1 observational study in people have been published, and 24 trials are registered.
About aging
Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
Phase 2/3Recruiting
Phase 3Completed
A Study to Find the Best Dose of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause
Phase 2Completed
Phase 3Completed
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause
Phase 2Completed
Phase 3Completed
All 16Fewer
Approved
May 12, 2023Menopause, vasomotor symptoms, vasomotor symptoms due to menopause, moderate-to-severe vasomotor symptoms
Dec 7, 2023Menopause, Hot Flashes, vasomotor symptoms, moderate to severe vasomotor symptoms associated with menopause
Repurposing
Phase 1Completed1 trial
Phase 1Completed1 trial
Every condition in trials
Menopause hot flashes
Phase 2/3Recruiting1 trial
Menopause related conditions
Phase 2/3Recruiting1 trial
Prostatic neoplasm
Phase 2Recruiting3 trials
Readouts due
- Apr 30, 2027
Who is developing fezolinetant?
3 companies: Astellas Pharma, Astellas Pharma Global Development and Astellas Pharma China.
Trial sponsors
Company18 trialsPhase 36,327 people
Company1 trialPhase 287 people
University of Colorado, Denver
1 trialPhase 2/3200 people
Chinese University of Hong Kong
1 trialPhase 254 people
1 trialPhase 232 people
University of Michigan Rogel Cancer Center
1 trialPhase 29 people
Funding
1 grant since 2025Swiss National Science FoundationCHF 4.9K
How this record changed
Summary written from the findings.